Advertisement

Alpelisib Plus Fulvestrant Approved for PIK3CA-Mutated Breast Cancer


Advertisement
Get Permission

On May 24, the U.S. Food and Drug Administration (FDA) approved the PIK3CA inhibitor alpelisib (Piqray) tablets to be used in combination with the FDA-approved endocrine therapy fulvestrant to treat postmenopausal women and men with hormone receptor–positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following disease progression on or after an endocrine-based regimen. Approval was based on the results of the SOLAR-1 trial.

The FDA also approved the companion diagnostic therascreen PIK3CA RGQ PCR Kit to detect the PIK3CA mutation in a tissue and/or a liquid biopsy. Patients who tested negative on the therascreen test using the liquid biopsy should undergo tumor biopsy for PIK3CA mutation testing.

In the double-blind trial, 572 patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. Patients were then randomly assigned to receive alpelisib at 300 mg/d plus fulvestrant at 500 mg every 28 days and once on day 15 or placebo plus fulvestrant. In the cohort with -PIK3CA-mutated cancer, 169 patients received treatment with alpelisib/fulvestrant and 172 received placebo/fulvestrant; in the cohort without PIK3CA mutation, 115 received alpelisib/fulvestrant and 116 received placebo/fulvestrant.

The median follow-up was 20 months. Among the 341 patients with PIK3CA mutations, the median progression-free survival was 11.0 months with alpelisib vs 5.7 months with placebo (hazard ratio [HR] = 0.65, P < .001). In this cohort, the overall response rate was 26.6% vs 12.8%. In the cohort of 231 patients without PIK3CA mutation, the median progression-free survival was 7.4 months vs 5.6 months (HR = 0.85).

Among all patients, the most common grade 3 or 4 adverse events in the alpelisib group were hyperglycemia and rash. 


Advertisement

Advertisement



;
Advertisement